<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-alpha) inhibitors are effective in the treatment of various inflammatory rheumatic conditions </plain></SENT>
<SENT sid="1" pm="."><plain>Increased risks of serious <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> are the major issues concerning the long-term safety of these agents </plain></SENT>
<SENT sid="2" pm="."><plain>We present a case of a young male <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s patient whose disease was complicated by cytomegalovirus (CMV) <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002583'>Colitis</z:hpo> started 10 d after the third Infliximab dose and responded to the cessation of TNF blocking treatment and administration of <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha and interferon gamma act at several levels in combating <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infections</z:e> should be kept in mind and included in the differential diagnosis of severe gastrointestinal symptoms in patients receiving anti-TNF agents </plain></SENT>
</text></document>